Preface
Spotlight on tumor mutational burden in patients with non-small cell lung carcinoma
Abstract
In the last recent years, immune checkpoint inhibitors directed against programmed cell death-1 (PD-1) and its ligand programmed death-ligand 1 (PD-L1), have strongly changed the treatment paradigm of patients with non-small cell lung cancer (NSCLC).
